Offer - Urjas Oil for just ₹ 1 X
Olmewon Plus is an allopathic medicine The correct dosage of Olmewon Plus depends on the patient's age, gender, and medical history. This information has been provided in detail in the dosage section.
Olmewon Plus is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Is the use of Olmewon Plus safe for pregnant women?
Pregnant women can take Olmewon Plus safely.
Is the use of Olmewon Plus safe during breastfeeding?
Olmewon Plus is safe for breastfeeding women.
What is the effect of Olmewon Plus on the Kidneys?
Olmewon Plus rarely harms the kidneys.
What is the effect of Olmewon Plus on the Liver?
Side effects of Olmewon Plus rarely affect the liver.
What is the effect of Olmewon Plus on the Heart?
Very few cases of side effects of Olmewon Plus on the heart have been reported.
Olmewon Plus should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Olmewon Plus unless your doctor advises you to do so -
Is this Olmewon Plus habit forming or addictive?
Olmewon Plus is not addictive in nature.
Interaction between Food and Olmewon Plus
Eating certain foods may increase the time it takes Olmewon Plus to have an effect. You should consult your doctor about it.
Interaction between Alcohol and Olmewon Plus
Consumption of alcohol and Olmewon Plus together may have severe effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Benicar (olmesartan medoxomil)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 507
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 169-173
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Norvasc® (amlodipine besylate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 540, 549, 550
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 147-148
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Hydrochlorothiazide
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 582-586
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 446-448